Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04086121 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT04086121 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 14 participants.
The verdict
NCT04086121, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032
Interventions
- DRUG Spesolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04086121
The ClinicalTrials.gov registry entry for NCT04086121 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spesolimab is the first listed.
NCT04086121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04086121 about?
NCT04086121 is a clinical study titled "A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032". To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032
What is the current status of trial NCT04086121?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-09-24. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04086121?
The interventions under investigation include: Spesolimab (DRUG).
Who is sponsoring clinical trial NCT04086121?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.